Adagrasib package insert

insert inserted insertion inside insider insight insights inspection package packages packaging packard packed packet packets packing packs pad

Adagrasib bonds with and inactivates the variant KRAS G12C cysteine protein, rendering the cells less viable, stopping the tumor’s ability to proliferate, and leading to tumor regression. decreased leukocytes/neutrophils, and increased alkaline phosphatase. The package insert contains warnings for gastrointestinal adverse reactions

Package insert. Aadi Bioscience, Inc.: Pacific Palisades, CA; December 2025. Athymic mice (n = 5 per treatment group) bearing subcutaneous NSCLC xenografts (NCI-H2122; KRAS G12C, STK11 null, TP53 C176F) in both flanks were treated with the following, adagrasib versus everolimus plus adagrasib (p = 0.09) (Figure 1B)

− Adagrasib − Fam-trastuzumab -nxki Ado-trastuzumab emtansine IV. Libtayo [package insert]. Tarrytown, NY; Regeneron Pharmaceuticals, Inc.; April 2025. Accessed November 2025. Moda Health Plan, Inc. Medical Necessity Criteria Page 6/11 Proprietary

Monitoring drug levels may be indicated. RESOURCES. Tobramycin Package Insert Gentamicin Package Insert Amikacin Package Insert Streptomycin Package

Start warfarin and stop apixaban 3 days later, or stop apixaban Pradaxa package insert Eliquis package insert Xarelto package insert.

FDA Package Inserts EUAs. RSV: Mresvia Package Insert. Moderna. View PDF Moderna Product Approval. RSV: Beyfortus Package Insert. Sanofi.

Glofitamab [package insert]. Genetech US, Inc. Epcoritamab [package insert]. Genmab US, Inc.LUNSUMIO [package insert]. Genentech, Inc. Page

Adagrasib is a CYP3A, CYP2C9, CYP2D6P-glycoprotein (, and P-gp) inhibitor. Concomitant use with sensitive CYP3A, CYP2C9, CYP2D6 -gp substrates should be avoided or P due to the increased risk of adverse reactions from the substrate, unless otherwise directed in the substrate package insert.